Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 29 of April 2025 to Question 46588 on Abiraterone, what discussions she has had with NICE on its engagement with health authorities on the (a) appraisal and (b) use of abiraterone acetate for high-risk non-metastatic prostate cancer.

The Department has had no such discussions. Abiraterone does not have a marketing authorisation for use in the treatment of high-risk, non-metastatic prostate cancer and has not been evaluated for that indication by the National Institute for Health and Care Excellence (NICE). The NICE makes recommendations for the National Health Service in England on the vast majority of new and significant licence indications, but does not evaluate medicines that are used outside their marketing authorisations or “off-label”.

NHS England considered abiraterone as an off-label treatment for the treatment of hormone sensitive, non-metastatic prostate cancer through its clinical policy development process in 2024/25. Through this process NHS England confirmed that there was sufficient supporting evidence to support the routine commissioning of abiraterone in this indication, but it has not been possible to identify the necessary recurrent funding to support the commissioning of abiraterone for this purpose, or any other treatments within the prioritisation round. Should the funding position change and a further prioritisation round take place, abiraterone for the treatment of hormone sensitive, non-metastatic prostate cancer will be reconsidered.